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Abstract
A goal for an HIV-1 vaccine is to overcome virus variability by inducing broadly neutralizing 
antibodies (bnAbs). One key target of bnAbs is the glycan-polypeptide at the base of the envelope 
(Env) third variable loop (V3). We have designed and synthesized a homogeneous minimal 
immunogen with high-mannose glycans reflective of a native Env V3-glycan bnAb epitope (Man9-
V3). V3-glycan bnAbs bound to Man9-V3 glycopeptide and native-like gp140 trimers with similar 
affinities. Fluorophore-labeled Man9-V3 glycopeptides bound to bnAb memory B cells and were 
able to be used to isolate a V3-glycan bnAb from an HIV-1–infected individual. In rhesus 
macaques, immunization with Man9-V3 induced V3-glycan-targeted antibodies. Thus, the Man9-
V3 glycopeptide closely mimics an HIV-1 V3-glycan bnAb epitope and can be used to isolate V3-
glycan bnAbs.
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INTRODUCTION
One strategy for the induction of HIV-1 glycan-directed broadly neutralizing antibodies 
(bnAbs) is to express trimeric forms of the envelope (Env) in structures that mimic the native 
trimer and bind to germ line–expressing naïve B cells (1). One problem for HIV-1 vaccine 
development has been the difficulty in design of such immunogens. Important criteria of Env 
nativeness are (i) that an HIV-1 antigen binds to bnAbs and (ii) that it can be used as a 
fluorophore-labeled protein for isolating bnAb-producing memory B cells by binding their B 
cell receptors (BCRs) (2–5) One such structural design recently reported is the BG505 
SOSIP.664 Env trimer protein that presents a native-like Env conformation and is recognized 
by several classes of trimer-specific bnAbs (6–10). An alternative strategy for mimicking 
glycan bnAb epitopes is to produce immunogens that mimic HIV Env epitopes recognized 
by bnAb germline antibodies (11), while minimally presenting dominant strain-specific 
epitopes (12–15), either alone or in the context of heterologous protein scaffolds (16).
In studying the ontogeny of the V3-glycan bnAb DH270 lineage isolated from an African 
HIV-infected individual, we found that the un-mutated common ancestor (UCA) antibody 
for the DH270 lineage did not bind HIV-1 Env glycoprotein, either in solution or when 
expressed as a trimer on the cell surface (17). Here, we have synthesized a homogeneous and 
conformationally stable glycopeptide bearing two high-mannose undecasaccharides (Man9) 
that binds to HIV-1 V3 bnAbs with affinities similar to that of the native-like BG505.664 
SOSIP trimer. We have isolated members of a V3-glycan bnAb clonal lineage using either 
the synthetic fluorophore-labeled Man9-V3 or SOSIP trimers, thus demonstrating that Man9-
V3 mimicked the HIV-1 V3-glycan bnAb epitope. Furthermore, the Man9-V3 glycopeptide 
bound the UCA of the DH270 V3-glycan bnAb lineage (17) and induced V3-glycan–
targeted antibodies in rhesus macaques.
RESULTS
Synthesis of Man9-V3 glycopeptide
The crystal structure of the HIV-1 V3 bnAb PGT128 in complex with the gp120 Env outer 
domain containing a truncated V3 loop revealed the key antibody contacts with its 
glycosylated epitope (Fig. 1) (18). We synthesized a glycopeptide (Man9-V3) that is based 
on the clade B JRFL HIV-1 isolate composed of the discontinuous epitope of PGT128 with 
deletion of residues 305 to 320, retention of P321, and stabilization by a disulfide bridge 
between C296 and C331 (Fig. 1) (18). Man9-V3 glycopeptide was chemically synthesized 
using a similar approach used to produce V1V2 glycopeptides (13). As controls, a 
biotinylated aglycone V3 peptide with no high-mannose glycans (Fig. 1) and a biotinylated 
Man9 free glycan (Fig. 1 and Supplementary Materials, compound 9) were also synthesized.
Antigenicity of Man9-V3 glycopeptide
In biolayer interferometry (BLI) measurements, the V3-glycan bnAbs PGT128 and PGT125 
bound specifically to Man9-V3 glycopeptide but not to aglycone V3 peptide, as did the 
lectin concanavalin A (fig. S1A), which binds to both mannose and glucose. Monoclonal 
antibody (mAb) 2G12, which makes central contacts with the terminal mannose units at the 
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tip of the D1 arm of high-mannose glycans (19), also bound to Man9-V3 glycopeptide but 
not to aglycone V3 peptide (fig. S1A). Each of the N332-glycan–dependent bnAbs (PGT128 
and PGT125) showed stronger binding to Man9-V3 glycopeptide than to glycan only (Man9) 
(fig. S1B), indicating that bnAb contacts with the V3 polypeptide in addition to Man9 
glycans (18). In enzyme-linked immunosorbent assay (ELISA), the half-maximal effective 
concentration (EC50) of PGT128 (0.35 μg/ml) to Man9-V3 was fivefold lower than that of 
PGT125 (1.75 μg/ml) (Fig. 2A). Apparent equilibrium dissociation constant (Kd) 
measurements by BLI of Man9-V3 binding gave monovalent Kd values of 326 and 706 nM 
for PGT128 and PGT125, respectively (Fig. 2, B and C). However, binding of both V3 
bnAbs was biphasic and strongly influenced by avidity effects, with PGT128-binding Kd 
being enhanced to 44 nM for the bivalent mode of binding (fig. S7A), indicating that the 
bivalent avidity effect could enhance the overall affinity by nearly an order of magnitude and 
likely mimicking the proposed cross-linking of viral Env spikes during PGT128 
neutralization (18). Thus, the synthetic Man9-V3 glycopeptide presented conformational 
epitopes required for glycan-dependent PGT128 and PGT125 bnAb binding. In addition, the 
high-mannose glycans presented on Man9-V3 were appropriately spaced for the binding of 
the glycan-targeting bnAb 2G12 (fig. S1A).
Isolation of N332-dependent clonal B cell lineage members
Plasma from the HIV-infected individual CH765 was predicted to have PGT128-like bnAb 
neutralization activity using a bnAb mapping analysis algorithm (20) (fig. S2A). CH765 
plasma showed N332-dependent neutralization activity (fig. S2B) and showed binding to 
Man9-V3 but not to aglycone V3 (Fig. 3A). The SOSIP Env gp140 trimers present native-
like Env conformations and BG505 SOSIP trimer as an affinity bait has been used to isolate 
quaternary bnAbs from blood memory B cells of an HIV-1–infected individual (3, 5, 10, 21). 
Therefore, using fluorophore-labeled native-like BG505 SOSIP trimers to bind to memory 
BCRs (10), we decorated memory B cells from donor CH765 with clade A 
BG505.T332N.SOSIP and clade C Env DU156.12.SOSIP gp140 trimer proteins. Dual 
SOSIP trimer–positive memory B cells were single cell–sorted, and immunoglobulin (Ig) 
heavy- and light-chain genes were amplified and recombinantly expressed (fig. S3A, table 
S1, and data set S3) (10). We isolated two antibodies, CH765-VRC41.01 and CH765-
VRC41.02 (Fig. 3B). Similarly, mAb DH563 (Fig. 3B) was isolated after flow sorting of 
CH765 blood memory B cells decorated with fluorophore-labeled Man9-V3 glycopeptide 
(fig. S3B, table S1, and data set S3). VRC41.01, VRC 41.02, and DH563 were clonally 
related (Fig. 3C); used VH4–39 and Vκ4–69 heavy- and light-chain gene families, 
respectively; and had 20 to 21% VH (variable region of immunoglobulin heavy chain) 
nucleotide mutations and a heavy-chain complementarity determining region 3 (HCDR3) 
length of 21 amino acids (table S1).
Specificity of VRC41.01, VRC41.02, and DH563 antibodies
Binding of the isolated antibodies to HIV-1 Env was N332-dependent (fig. S4A), and site-
directed mutagenesis of the BG505.W6M.C2 pseudovirus demonstrated VRC41.01 and 
VRC41.02 to be dependent on the N332 glycan for HIV-1 neutralization (fig. S4B). Further 
mapping on JRCSF.DB pseudovirus demonstrated VRC41.01 and VRC 41.02 to be sensitive 
to N301A and N392A mutations, but not to N295A, N339A, and T297A mutations (fig. S4C). 
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Both PGT128 and VRC41.01 exhibited a similar phenotype, whereas PGT121 was sensitive 
only to the N392A mutation (fig. S4C). DH563, VRC41.01, and VRC41.02 mAbs reacted 
with Man9-V3 glycopeptide but not with aglycone V3 peptide (fig. S5).
Like PGT128, positive autoreactivity in HEp-2 cell staining was observed for VRC41.01, 
whereas both VRC41.02 and DH563 did not react with HEp-2 cells (fig. S6). In a glycan 
array analysis, VRC41.01 gave a glycan binding profile that was similar to that of PGT128 
by showing preferential binding to high-mannose glycans (Man7, Man8, and Man9) (Fig. 
3D). VRC41.01 also showed weaker responses to lower-order oligomannose glycans (Man5 
and Man6) that did not bind to PGT128 (Fig. 3D). No detectable binding of the free glycans 
to either DH563 or VRC41.02 was observed (Fig. 3D).
Affinity of V3-glycan bnAb binding to Man9-V3 glycopeptide and native-like SOSIP trimers
We compared affinities of the V3-glycan bnAbs VRC41.01, VRC41.02, and DH563 for 
Man9-V3 glycopeptide and BG505 T332N SOSIP trimer (summarized in Fig. 3E). 
VRC41.01 bound to Man9-V3 with an apparent Kd of 56 nM (Fig. 3E and fig. S7B), which 
was similar to the affinity values of PGT128 binding to Man9-V3 (Fig. 3E and fig. S7A). 
Man9-V3 affinities of both VRC41.02 (Fig. 3E and fig. S7C) and DH563 (Fig. 3E and fig. 
S7D) were weaker than that of VRC41.01 (Kd = 157 nM and Kd = 173 nM for VRC41.02 
and DH563, respectively). As observed with Man9-V3 glycopeptide, VRC41.01 bound to 
BG505. T332N. SOSIP gp140 with a Kd of 64.5 nM, which was similar to the affinity of 
PGT128 for the BG505 SOSIP (Kd = 41 nM) (Fig. 3E and fig. S8, A and B), whereas 
VRC41.02 bound with a weaker affinity of 166 nM (Fig. 3E and fig. S8C). However, DH563 
bound to BG505 SOSIP trimer with higher affinity (Kd = 46 nM) (Fig. 3E and fig. S8D) 
than it did to Man9-V3 glycopeptide (Kd = 173 nM) (Fig. 3E and fig. S7D). Thus, the 
affinities of the two VRC41 mAbs to BG505 SOSIP trimer were similar to their affinities for 
Man9-V3 glycopeptide (Fig. 3E).
Neutralization breadth and potency of N332-glycan–dependent mAbs
VRC41.01, VRC41.02, and DH563 V3-glycan bnAbs were tested for neutralization breadth 
and potency against 30 HIV pseudoviruses (Fig. 3F and table S2). VRC41.01 was the 
broadest and most potent of the DH563-VRC41 clones, neutralizing 63% of viruses with a 
median inhibitory concentration (IC50) of 0.091 μg/ml. VRC41.01 was tested in a larger 
panel of 177 pseudoviruses and neutralized 56% of viruses with an IC50 of 0.620 μg/ml (fig. 
S9 and data set S2). Thus, using Man9-V3 or native-like SOSIP trimers, we isolated from an 
HIV-infected individual three V3-glycan–specific bnAbs that belong to the same B cell 
clonal lineage.
Immunogenicity of Man9-V3 glycopeptide in rhesus macaques
To test whether the synthetic Man9-V3 glycoepeptide would induce antibodies that target the 
V3-glycan epitope, we immunized four rhesus macaques with monomeric Man9-V3 
glycopeptide formulated in the Toll-like receptor 4 agonist GLA-SE (glucopyranosyl lipid 
adjuvant–stable emulsion) adjuvant in a dose escalation study (50 to 500 μg of glycopeptide) 
(Fig. 4A). We detected plasma antibody binding in two of four macaques (#5994 and #5996) 
to both Man9-V3 and aglycone V3 after the third 100-μg dose immunization. For macaque 
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#5994, higher titers of vaccine-induced responses were boosted with a higher-dose boost 
(500 μg) of Man9-V3 glycopeptide (Fig. 4B). By flow sorting of Man9-V3-AF647 and 
aglycone V3-BV421 decorated blood memory B cells from both animals (#5994 and #5996) 
harvested at either week 20 or week 52 after the final immunization, we isolated five mAbs 
that bound Man9-V3 glycopeptide or aglycone V3 peptide constructs (figs. S10 and S11 and 
table S3). Four of the antibodies used VH3 and one used VH4 gene segments; VH mutation 
frequencies ranged from 2% (DH707) to 11 to 12% (DH706, DH708, and DH710) (table 
S3). A variety of light chains were used, but all were Vλ(variable light chain λ) (table S3). 
Three antibodies (DH706, DH708, and DH710) selectively bound to Man9-V3 glycopeptide, 
but not to aglycone V3, and two of them (DH706 and DH710) bound to CH848 transmitted 
founder (TF) gp120 and Consensus C (ConC) gp120 HIV-1 Envs (Fig. 4C and fig. S11). 
Deletion of the N-linked glycan at position N332 of the HIV-1 V3 loop resulted in decreased 
binding of DH706 and DH710 to the CH848 TF gp120 Env, compared to the wild type (Fig. 
4C and fig. S11). DH706 and DH710 were tested for binding to JRFL and B.63521 Env 
glycoproteins grown either in the absence or in the presence of kifunensine, an endoplasmic 
reticulum mannosidase I inhibitor, to promote the density of N-linked high-mannose 
residues of the Env surface (22, 23). DH706 and DH710 preferentially bound Envs grown in 
the presence of kifunensine, suggesting that their binding to HIV-1 Env glycoproteins relied 
in part on high-mannose glycans (Fig. 4C). However, neither of these antibodies neutralized 
JRFL Env pseudoviruses when grown in the presence of kifunensine, indicating that the 
isolated mAbs are likely representative antibodies that lack sufficient HCDR3 length to bind 
to the V3-glycan site on virions with high affinity. A hallmark of V3-glycan bnAb UCAs is 
equal binding of Man9-V3 glycopeptide and aglycone (17). mAb DH707 bound equally well 
to both aglycone and Man9-V3 glycopeptide and had only 2% VH mutations (fig. S11 and 
table S3). Thus, the Man9-V3 glycopeptide induced antibody responses (for example, 
DH760 and DH710) in macaques targeted near the V3-glycan bnAb site.
DISCUSSION
Here, we show that the synthetic Man9-V3 glycopeptide can be used to isolate V3-glycan 
bnAbs and can bind to mature V3-glycan bnAbs with similar affinities to native-like SOSIP 
trimers. That fluorophore-labeled Man9-V3 glycopeptide can be recognized by V3-glycan 
bnAb memory BCRs attests to the ability of Man9-V3 glycopeptide to mimic a V3-glycan 
HIV-1 Env bnAb epitope. In a companion study, the Man9-V3 glycopeptide was successful 
in isolation of the most potent bnAb (DH270.6) of the DH270 V3-glycan lineage and also 
successfully used in isolation of the DH475 N332-dependent cooperating B cell lineage 
antibody (17). Thus, the Man9-V3 glycopeptide could be recognized not only by soluble 
bnAbs but also in the context of surface memory BCR expression.
The chemical synthesis process used for the production of the Man9-V3 glycopeptide is 
distinct from the previously reported elegant synthesis of a full-length V3 glycopeptide that 
was synthesized using an endoglycosidase-catalyzed transglycosylation process to 
incorporate N-linked glycans (15). The Li et al. construct was designed to incorporate 
glycans at sites recognized by 2G12 (15, 24). Furthermore, Li et al. had pentasaccharides 
with Man3 (GlcNAc2-Man3) at both positions (N295 and N332) (15), whereas the 
glycopeptide described here had GlcNAc2-Man9 at both positions N301 and N332. It is 
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notable that our V3 glycopeptide included the epitope sequences of the construct bound by 
PGT128 in its complex with the truncated outer domain eODmV3 (18). The apparent 
affinity (EC50) by ELISA analysis of PGT128 IgG binding to eODmV3 was reported to be 
46 nM (18), which is an order of magnitude weaker than PGT128 binding to Man9-V3 
(EC50 = 2.3 nM; Fig. 2A). Furthermore, the EC50 of PGT128 binding to cell surface trimer 
(2.8 nM) (18) is similar to the EC50 of its binding to the Man9-V3 glycopeptide (2.3 nM; 
Fig. 2A). The antigenic elements of PGT128 epitope are therefore well preserved in our 
synthetic Man9-V3 glycopeptide.
A major question has been what form of Env could initiate V3-glycan bnAb lineages. 
Neither soluble Env gp120 nor Env trimers bind V3-glycan bnAb soluble UCAs (17, 25). 
Bonsignori et al. have demonstrated that the Man9-V3 glycopeptide and its aglycone form 
bind the UCA of the DH270 V3-glycan bnAb lineage (17). With affinity maturation in the 
DH270 bnAb, binding to the aglycone V3 diminished and binding to Man9-V3 was 
increased (17). These observations raise the hypothesis that initiating immunogens for V3-
glycan lineages may be denatured or Env fragments, which have been postulated to be the 
majority of Env present in infected cells (17, 26–28).
Our immunogenicity studies demonstrated that the monomeric V3 glycopeptide is not a 
potent immunogen, but rather could serve as a prime for subsequent boosts with Env 
immunogens that derive from evolved Envs from individuals that make V3-glycan bnAbs 
(17). Thus, as a monomer, the V3 glycopeptide primed precursors of V3-glycan B cell 
lineages to clonally expand. One induced antibody bound both the aglycone and the V3 
glycopeptide, a trait of early precursors of V3-glycan bnAb lineages (17). Other isolated 
antibodies selectively bound only the Man9-V3 glycopeptide and thus were dependent on 
binding to glycans at the V3 base. The next steps of the work are now multimerizing the V3 
glycopeptide for higher-affinity BCR binding and then combining the Man9-V3 
glycopeptide prime with boosts of sequential Envs that, in an infected individual, induced 
bnAbs in HIV infection (17).
A limitation of this study is that immunizations were undertaken with the V3 glycopeptide 
monomer that did not have added T helper epitopes. We expect that multimerized V3 
glycopeptide with added T helper epitopes will improve its immunogenicity. Second, the V3 
glycopeptide only mimics PGT128-like V3-glycan bnAbs and does not mimic bnAbs that 
bind to complex glycans. Additional glycopeptides will be required to mimic other glycan-
targeted bnAb sites. Nonetheless, the homogeneous Man9-V3 glycopeptide mimics an 
HIV-1 Env V3-glycan bnAb epitope and can be used to define the memory B cell repertoire 
producing bnAbs, as well as to isolate V3-glycan bnAbs.
MATERIALS AND METHODS
Study design
The objective of the study was to design and synthesize a glycopeptide immunogen, bearing 
high-mannose glycans on two key asparagine residues (N332/N301), that mimics the epitope 
of a prevalent class of bnAbs that target the V3-glycan region of HIV-1 Env. An HIV-1–
chronically infected donor (CH765) was recruited for plasma specimen based on V3-glycan 
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PGT128-like bnAb neutralization activity. Isolation of V3-glycan bnAbs was performed by 
labeling of both synthetic glycopeptide and SOSIP gp140 trimers with fluorophores and by 
flow cytometric sorting of antigen-specific memory B cells. Independent sorting with both 
SOSIP gp140 trimers and Man9-V3 glycopeptide allowed the isolation from the CH765 
donor plasma of three V3-glycan bnAbs that belong to the same lineage. Each isolated mAb 
was characterized by immunogenetics, glycan and Env binding, and neutralization breadth 
and potency analyses. Finally, the synthetic glycopeptide was used as an immunogen in 
rhesus macaques to test whether Man9-V3 could induce antibodies that target the V3-glycan 
bnAb epitope. Five mAbs were isolated from blood memory B cells of immunized rhesus, 
and the mAbs were characterized for immunogenetics, glycan-dependent binding to Env 
proteins, and neutralization.
Human specimens
All work related to human subjects was in compliance with Institutional Review Board 
protocols approved by the Duke University Health System Institutional Review Board and 
the local ethics board at the site of enrollment. The participant in this study, an HIV-1–
chronically infected donor (CH765, precise time of infection unknown), was recruited into 
the CHAVI 001 (Center for HIV/AIDS Vaccine Immunology 001) study, and blood obtained 
was processed to isolate peripheral blood mononuclear cells (PBMCs) that were stored in 
the vapor phase of liquid nitrogen tanks before their use in this study.
Synthesis of Man9-V3 glycopeptide
A 30–amino acid V3 glycopeptide with oligomannose (Man9-V3) glycans, based on the 
clade B JRFL mini-V3 construct (18), was chemically synthesized, as described earlier (13). 
A full description of the chemical synthesis is detailed in the Supplementary Text, and 
synthesis fragments are listed in bold reference to those fully described in the 
Supplementary Text. Briefly, linear trisaccharide glycosyl donor S13 was synthesized with 
standard procedures and coupled to the core trisaccharide S14 at C3 of the branching 
mannose residue under solvent-directing conditions. Subsequent removal of benzylidine 
furnished the desired glycosyl acceptor for the challenging regioslective [6+5] glycosylation 
at C6 of the aforementioned bridging mannose residue. Synthesis of branched 
pentasaccharide glycosyl donor S12 was achieved with an efficient double mannosylation of 
a mannose thioglycoside S23. With these complex coupling partners in hand, glycosyl donor 
S12 and acceptor S29 were brought together with complete control of regioselectivity to 
furnish the desired fully protected Man9GlcNAc2 S30. Subsequent three-stage deprotection, 
purification, and Kochetkov anomeric amination furnished the desired β-glycosylamine 3 
ready for installation on the peptide. Using our one-flask aspartylation/deprotection protocol 
(29), Man9GlcNAc2 glycosyl amine 3 was joined to the free carboxylic acid side chain at 
position 301 on fragment 4 and at position 332 on fragment 5, followed by trifluoroacetic 
acid treatment to provide glycopeptide thioester 6 and N-terminal cysteinyl glycopeptide 7. 
These two fragments were then joined by native chemical ligation, immediately followed by 
cyclization via disulfide formation to afford Man9-V3-biotin. The control peptide, aglycone 
V3-biotin 2, had an amino acid sequence identical to that of Man9-V3-biotin 1.
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Man9GlcNAc2 (9) glycan synthesis
A full description of the chemical synthesis of 9 is detailed in the Supplementary Materials.
Briefly, Man9GlcNAc2–NH2 3 was treated with Biotin-OSu in dimethyl sulfoxide in the 
presence of 1-hydroxy-7-azabenzotriazole and N,N-diisopropylethylamine. After 
lyophilization, the product was purified by size exclusion chromatography to afford 
Man9GlcNAc2–NH–biotin 9.
Production of SOSIP trimers
HIV-1 gp140 SOSIP-type molecules based on clade A strain BG505 (6, 8) and clade C strain 
DU156.12 (30) including the mutations (A501C and T605C), the isoleucine-to-proline 
mutation at residue 559 (I559P), the glycan site at residue 332 (T332N), the mutation of the 
cleavage site to 6R (REKR to RRRRRR), and the truncation of the C terminus to residue 
664 (all HIV-1 Env numbering according to the HX nomenclature) were used in this study. 
The BG505 SOSIP construct also encoded a C-terminal two–amino acid glycine-serine 
linker followed by an Avi-tag, whereas the DU156.12 construct encoded a C-terminal five–
amino acid glycine-serine linker, a Thrombin cleavage site, a His6 purification tag, and a 
Strep-Tactin II purification tag followed by the Avi-tag sequence. The two HIV-1 SOSIP 
molecules were expressed as previously described (7) by cotransfecting with furin in human 
embryonic kidney 293F cells using 600 μg of HIV-1 SOSIP DNA and 150 μg of furin 
plasmid DNA. Transfection supernatants were harvested after 7 days, and the BG505 HIV-1 
trimer supernatant was passed over either a 2G12 antibody– or VRC01 antibody–affinity 
column. After washing with phosphate-buffered saline (PBS), bound protein was eluted with 
3 M MgCl2 and 10 mM tris (pH 8.0). The eluate was concentrated to less than 4 ml with a 
Centricon-70 concentrator and applied to a 16/60 Superdex 200 column equilibrated in PBS. 
The DU156.12 HIV-1 trimer was purified by nickel and Strep-Tactin–affinity 
chromatography, followed by size exclusion chromatography using a Superdex 200 column 
equilibrated in PBS. In both cases, the peaks corresponding to trimeric HIV-1 Env were 
identified, pooled, concentrated, and either used immediately or flash-frozen in liquid 
nitrogen and stored at −80°C.
Antibody binding affinity measurements
Antibody binding to synthetic glycopeptide or to SOSIP gp140 trimers was measured by 
BLI (Pall ForteBio Octet RED96) analysis. The BLI assay was performed using 
streptavidin-coated sensors (Pall ForteBio) to capture either biotin-tagged Man9-V3 
glycopeptide or aglycone V3 peptide. The V3 peptide–immobilized sensors were dipped 
into varying concentrations of antibodies after blocking of sensors in 0.1% bovine serum 
albumin (BSA). Antibody concentrations ranged from 0.5 to 150 μg/ml, and nonspecific 
binding interactions were subtracted using the control anti–respiratory syncytial virus mAb 
palivizumab (Synagis). Rate constants and apparent Kd were calculated by global curve 
fitting analyses to the bivalent avidity model of binding responses with a 10- to 15-min 
association and 15-min dissociation interaction time. The apparent Kd values for monovalent 
interactions of the antibodies were estimated using the faster components of the association 
and dissociation rates ka1 and kd1, respectively. For binding to Man9-V3 glycopeptide or 
BG505 SOSIP gp140 where avidity effects were strong and binding curves could not be 
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resolved into their components, apparent Kd values were derived using dose-response curves 
at varying antibody concentrations (0.5 to 80 μg/ml) and using a nonlinear four-paramater 
curve fitting analysis.
Isolation of DH563 mAb
Biotinylated Man9-V3 peptides were tetramerized via streptavidin and conjugated with 
either AF647 (Thermo Scientific) or BV421 (BioLegend) dyes. Peptide tetramer quality 
after conjugation was assessed by flow cytometry to a panel of well-characterized HIV-1 
V3-glycan antibodies (PGT128 and 2G12) and linear V3 antibodies (F39F) attached to 
polymer beads. PBMCs from donor CH765 were stained with LIVE/DEAD Fixable Aqua 
Stain (Thermo Scientific), anti-human IgM [fluorescein isothiocyanate (FITC)], CD3 (PE-
Cy5), CD235a (PE-Cy5), CD19 (APC-Cy7), and CD27 (PE-Cy7) (BD Biosciences); anti-
human antibodies against IgD (PE); anti-human antibodies against CD10 [ECD (R-
Phycoerythrim–Texas Red-X], CD38 (APC-AF700), CD19 (APC-Cy7), CD16 (BV570), 
and CD14 (BV605) (BioLegend); and Man9GlcNac2 V3 tetramer in both AF647 and 
BV421. PBMCs that were Aqua Stain−, CD14−, CD16−, CD3−, CD235a−, IgD−, positive for 
CD19+, and negative for surface IgD were defined as memory B cells; these cells were then 
gated for Man9-V3+ positivity in both AF647 and BV421 and were single cell–sorted using 
a BD FACSAria II into 96-well plates containing 20 μl of reverse transcriptase (RT) buffer. 
Complementary DNA (cDNA) synthesis was performed, as previously described (31). Ig 
heavy (VH) chains were polymerase chain reaction (PCR)–amplified using a nested 
approach. VH genes were amplified in the first round of amplification from (4), followed by 
nested amplification of VH, Vκ (variable light chain κ), and Vλ genes as performed in (32). 
Primers used are listed in data set S3. PCR products were analyzed on 2% SYBR Safe E-
Gels (Invitrogen). PCR-amplified VH and VL genes were purified and sequenced. Sequences 
were analyzed, and V(D)J arrangements were inferred using computational methods, as 
previously described (33, 34).
Isolation of VRC41.01 and VRC41.02 mAbs
Biotinylated BG505.T332N.SOSIP and DU156.12.SOSIP trimers were tetramerized via 
streptavidin-linked PE and APC (Invitrogen), respectively, as previously described (5, 35). 
Peptide tetramer quality after conjugation was assessed by flow cytometry to a panel of 
well-characterized HIV-1–specific bnAbs. PBMCs from donor CH765 were stained with 
LIVE/DEAD fixable violet dead cell dye (Invitrogen), anti-human IgG (FITC), anti-human 
CD19 (Cy7-PE), anti-human CD3 (Cy7-APC), anti-human CD8 (BV711), anti-human 
CD14 (BV605), BG505.T332N.SOSIP trimer (PE), and DU156.12.SOSIP trimer (APC). 
PBMCs that were violet dye−, CD3−, CD8−, CD14−, CD19+, IgG+, and 
BG505.T332N.SOSIP+ and/or DU156.12.SOSIP+ were single cell–sorted using a BD 
FACSAria II into 96-well plates containing 20 μl of RT buffer, and cDNA synthesis was 
performed, as previously described (20). Ig heavy (VH) and light (VL) chains were PCR-
amplified using a nested approach. First- and second-round amplification of VH, Vκ, and Vλ 
genes was carried out as in (20), with primers grouped as previously described (35). PCR 
products were analyzed on 1% 96-well ethidium bromide–stained precast gels (Embi Tec). 
PCR-amplified VH and VL genes were purified and sequenced. Sequences were analyzed, 
and V(D)J arrangements were inferred using IMGT/V-Quest (www.imgt.org).
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Transient and recombinant antibody expression
Transient and recombinant mAb production was performed, as previously described, for 
DH563 (32, 36). VRC41.01 and VRC41.02 were produced, as previously described (20).
Enzyme-linked immunosorbent assay
Screening of recombinant mAbs sorted with fluorophore-conjugated Man9-V3 was 
performed, as previously described (36). Transient transfected antibodies as well as purified 
DH563 were assessed for binding to heterologous Env (ConC gp120, VRCb gp120, and 
ConS gp140). N332 sensitivity was assessed by reduction in binding to N332A mutant Env 
compared to wild-type Env. Binding to Man9-V3-biotin and aglycone V3-biotin was 
determined as follows. Briefly, streptavidin (2 μg/ml) in coating buffer (0.1 M NaHCO3, pH 
9.6) was used to coat 384-well high-binding ELISA plates at 15 μl per well at 4°C overnight. 
Plates were washed with PBS + 0.05% Tween 20 and blocked with 3% BSA in PBS at room 
temperature for 1 hour. The blocked plates were washed and 10 μl of biotinylated Man9-V3 
and biotinylated aglycone V3 was diluted to 1 μg/ml in 1% BSA in PBS + 0.05% Tween 20 
at room temperature for 1 hour. Plates were again washed, and serial threefold dilutions of 
purified mAbs ranging from 0 to 100 μg/ml in 1% BSA in PBS + 0.05% Tween 20 were 
added and incubated at room temperature for 1 hour. After incubation, plates were washed 
twice and incubated with horseradish peroxidase (HRP) goat anti-human IgG (1:10,000) 
diluted in 1% BSA in PBS + 0.05% Tween 20 at room temperature for 1 hour. These plates 
were washed four times with and developed with tetramethyl benzidine substrate (20 μl per 
well) (SureBlue Reserve) for 15 min. The HRP reaction was stopped with 1 M HCl (20 μl 
per well), and OD (at 450 nm) was determined. The EC50 of mAbs to HIV-1 Env, Man9-V3, 
and aglycone V3 was determined and expressed as the concentration of mAb.
Antibody reactivity by indirect immunofluorescence
Indirect immunofluorescence binding of recombinant mAbs to HEp-2 cells (Inverness 
Medical Professional Diagnostics) was performed as follows. On a predetermined spot on an 
antinuclear antibody HEp-2 kit slide, 20 μl of antibody at 50 μg/ml was incubated for 25 min 
at room temperature, washed, and developed for 25 min with 20 μl of goat anti-human Ig-
FITC at 20 μg/ml (SouthernBiotech). All incubations were performed in humidified 
chambers in the dark. Before fixation, slides were washed and dried, and a drop of 33% 
glycerol was placed on each spot. Images were taken on an Olympus AX70 with SpotFlex 
FX1520 charge-coupled device with a UPlanFl 40× (numerical aperture, 0.75) objective at 
25°C in the FITC channel using SPOT software. All images were acquired for the time 
specified in the figure legend. Image layout and scaling were performed in Adobe Photoshop 
without image manipulation.
Neutralization assays
Antibody neutralizing activity was assessed via a TZM-bl cell-based neutralization assay 
(37). Neutralization breadth and potency for DH563/VRC41 family of V3-glycan antibodies 
were tested in a multi-clade panel of 30 tier 2 Env pseudoviruses. Neutralization breadth and 
potency of VRC41.01 against a panel of 177 geographically and genetically diverse Env 
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pseudoviruses representing the major subtypes and circulating recombinant forms were 
performed, as previously described (5, 20).
Oligomannose glycan array immunostaining
Custom glycan arrays printed in a 24-subarray format were purchased from Z Biotech. The 
natural source glycans GlcNAc2, Man5GlcNAc2, Man6GlcNAc2, Man7GlcNAc2 D1, 
Man7GlcNAc2 D3, Man8GlcNAc2 D1D3, and Man9GlcNAc2 were printed onto the array 
using hydrazide chemistry. Within each subarray, the glycans were printed in triplicate at 
100, 33, and 10 μM concentrations, and print buffer alone was printed as a background 
binding control. Human IgG was printed within each subarray to serve as a detection 
control. For immunostaining of each subarray, the arrays were placed in an ArraySlide-24 
holder (Gel Company). Each subarray was hydrated in Milli-Q (Millipore) water for 2 min. 
Hydrazide Glycan Blocking Buffer (Z Biotech) was used to block each subarray for 1 hour. 
The subarrays were sealed with adhesive foil and were shaken at 40 rpm during all 
incubation steps. The blocking buffer was aspirated, and antibody (50 μg/ml) diluted in 
Glycan Array Assay Buffer (Z Biotech) was incubated on an individual subarray for 1 hour. 
As a positive control, biotinylated concanavalin A (20 μg/ml) was assayed in parallel on 
each array. The array was washed five times with PBS + 0.05% Tween 20. Antibody binding 
to glycan was detected with a Cy3-conjugated anti-human IgG antibody (Sigma). 
Biotinylated concanavalin A binding was detected with Cy3-conjugated streptavidin 
(Sigma). The array was washed five times with PBS + 0.05% Tween 20 and one time with 
0.01 × PBS and spun dry. The fluorescence of each feature was read with a GenePix 4000B 
instrument (Molecular Devices) and quantified using GenePix software (version 7, 
Molecular Devices). Any fluorescence observed in the print buffer alone was subtracted 
from the mean fluorescence for each glycan.
Immunizations
Immunization of rhesus macaques and blood draws were performed at Bioqual Inc. 
according to the schedule in Fig. 4. Indian origin rhesus macaques were immunized 
intramuscularly with 50, 100, or 500 μg of Man9-V3 monomeric glycopeptide formulated in 
GLA-SE adjuvant, and blood samples were collected 2 weeks after immunization. All rhesus 
macaques were maintained in accordance with the Association for Assessment and 
Accreditation of Laboratory Animals. Research was conducted in compliance with the 
Animal Welfare Act and other federal statutes and regulations relating to animals and 
experiments involving animals and adheres to principles stated in the Guide for the Care and 
Use of Laboratory Animals (NRC Publication, 2011 edition).
Isolation of DH706-DH710 rhesus mAbs
Man9-V3 and/or aglycone V3–specific memory B cells from macaques #5994 and #5996 
were sorted by flow cytometry, as previously described (38). Briefly, 1 × 107 PBMCs were 
decorated with a B cell antibody panel that cross-reacts with rhesus B cells [CD14 (BV570), 
CD3 (peridinin chlorophyll protein–Cy5.5), CD20 (FITC), CD27 (APC-Cy7), and IgD (PE) 
(BD Biosciences)], AF647-tagged Man9-V3, and BV421-tagged aglycone V3. Antigen-
specific memory B cells were gated as D3−CD14−CD20+CD27+sIgD−, and antibodies were 
sorted [on the basis of the reactivities Man9-V3+, aglycone V3− (DH706, DH708, and 
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DH710), Man9-V3+, aglycone V3+ (DH707), and Man9-V3−, aglycone V3+ (DH709)] into 
96-well PCR plates containing 20 μl of reverse transcription reaction buffer that included 5 
μl of 5× first-strand cDNA buffer, 1.25 μl of dithiothreitol, 0.5 μl of RNaseOUT (Life 
Technologies), 0.0625 μl of Igepal (Sigma-Aldrich), and 13.25 μl of ultrapure deionized 
water (Life Technologies). Rhesus macaque VHDJH and VLJL segments were isolated by 
single-cell reverse transcription–PCR using methods previously described (39). Isolated 
V(D)J gene fragments were used for the construction of linear expression cassettes for 
production of recombinant mAbs in 293T cells (39).
Production of kifunensine-treated HIV-1 Envs
One milligram of plasmid Env DNA per liter of cells was diluted in 
Dulbecco’smodifiedEagle’smediumandmixedwithPEI(polyethylenimine). PEI:DNA 
mixtures were added to cells for 4 hours. 293F (Invitrogen) cells were subsequently washed 
and diluted to 1.25 million cells/ml in FreeStyle 293 medium (Invitrogen). In instances 
where high-mannose glycosylation was desired, kifunensine (Sigma-Aldrich) was dissolved 
in PBS and added once to the cell culture medium to a final concentration of 25 μM. The 
cells were cultured for 5 days, and on the fifth day, the cell culture medium was cleared of 
cells by centrifugation and filtered with a 0.8-μm filter. The cell culture was concentrated 
with a Vivaflow 50 (Sartorius) with a molecular mass cutoff of 10 kDa. The concentrated 
cell culture supernatant was rotated with lectin beads (Vistar Labs) overnight at 4°C. The 
beads were pelleted by centrifugation the next day and resuspended in MES wash buffer. 
The lectin beads were washed twice, and the protein was eluted with methyl-α-pyranoside. 
The protein was buffer-exchanged into PBS and stored at −80°C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Design of gp120 V3 domain broadly neutralizing epitope mimics
Structure of the chemically synthesized Man9-V3-biotin glycopeptide and of aglycone V3-
biotin. See procedures for synthesis in Supplementary Text and data set S1.
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Fig. 2. Man9-V3 glycopeptide binding to V3-glycan bnAbs PGT128 and PGT125
(A) ELISA binding analysis to calculate EC50 of PGT128 and PGT125 binding to Man9-V3 
glycopeptide. OD, optical density. (B and C) BLI binding analyses for Kd measurements for 
the binding of PGT128 (B) and PGT125 (C) to Man9-V3 glycopeptide. Kinetics rates (ka1 
and kd1) of the faster components (figs. S7 and S8) were derived from global curve fitting 
analysis to a bivalent avidity model and used to derive the apparent Kd values. Binding 
analysis for affinity measurements was carried out by BLI, as described in Materials and 
Methods. Data are representative of three and two independent experiments, respectively, for 
PGT128 and PGT125.
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Fig. 3. Isolation and characterization of N332-dependent antibodies isolated using native-like 
SOSIP trimers and synthetic Man9-V3 glycopeptide
(A) ELISA binding analyses of plasma from the HIV-infected donor CH765 to Man9-V3 
and aglycone V3 peptides. Donor plasma was screened in duplicate assays, and binding is 
represented as mean values. (B) Memory B cells from donor CH765 were decorated with 
either fluorophore-conjugated BG505.T332N.SOSIP and DU156.12.SOSIP in phycoerythrin 
(PE) and allophycocyanin (APC), or Man9-V3 tetramers tagged to SA–AF647 (Alexa Fluor 
647) and SA–BV421 (Brilliant Violet 421). The B cells from which CH765-VRC41.01, 
VRC41.02, and DH563 were cloned are indicated as green, red, and blue dots, respectively. 
(C) Immunogenetics and phylogeny of the DH563-VRC41 clonal lineage were inferred 
using Clonanalyst (33, 34). See also fig. S3. nt, nucleotide. (D) Reactivity of CH765-
VRC41.01, CH765-VRC41.02, and DH563 to Man5, Man6, Man7-D1, Man7-D3, Man8-
D1D3, and Man9 glycans, depicted on the right, printed on an array and detected via 
immunofluorescence. See also figs. S5 and S6. (E) Affinity measurements of newly isolated 
V3-glycan mAbs to Man9-V3 and BG505. T332N.SOSIP trimer were determined by BLI. 
Binding curves and data analysis are shown in figs. S7 and S8. (F) CH765-VRC41.01, 
VRC41.02, and DH563 were tested for neutralization breadth against a diverse panel of Env 
pseudoviruses using the TZM-bl assay. See also table S2 and fig. S9.
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Fig. 4. Immunogenicity of Man9-V3 glycopeptide in rhesus macaques
(A) Study design to assess immunogenicity of Man9-V3 in rhesus macaques. Monomeric 
Man9-V3 was formulated in GLA-SE adjuvant and injected intramuscularly in sequentially 
increasing doses, as indicated. (B) Plasma from immunized macaques was tested for binding 
to biotinylated Man9-V3 and aglycone V3 in ELISA, as described in Materials and Methods. 
(C) Man9-V3 reactive antibodies were isolated via antigen-specific memory B cell sorts and 
tested for binding to recombinant HIV-1 Envs in ELISA. See also fig. S11 and table S3. 
AUC, area under the curve.
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